ZELLUNA IMMUNOTHERAPY AS
Operating
Utvikle, markedsføre og selge medisinske produkter og utstyr samt det
som står i forbindelse med dette.
Utvikle legemidler mot kreft.
Organization
- CEO
- NJ
- Chairman of the board
- AT
Anders Tuv1978
- Years since formation
- 10 years
- since Mar 1, 2016
- Type
- Limited company
- VAT registered
- Yes
- Number of employees
- 11
Ownership
- Number of shares and share classes
- 13,524,826
- 1 share class
- Total number of shareholders
- 1
- company
- Belongs to group of
Financials
- Annual total result 2025
- -100,896,000
- NOK
- Total equity 2025
- 79,341,000
- NOK
Last update: Oct 13, 2026
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
NJ | Managing Director/CEO | - |
Board
| Name | Role | Shares |
|---|---|---|
AT 1978 | Chairman | - |
NJ | Board Member | - |
GC | Board Member | - |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - | |
| Accountant | - | |
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
CG | - | 2.23 % indirectly |
Last update: May 26, 2026
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 13,524,826 | 100 % |
Last update: Sep 25, 2026
Group structure
- Total operating income 2025: NOK 6,110,000Operating profit 2025: NOK -278,623,000Employees: 6
Financials
in NOK
Summary
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 0 | 53,000 | 7,891,998 | 13,300,000 | 13,125,003 |
Annual Total Result | -100,896,000 | -105,162,000 | -86,807,393 | -49,071,731 | -35,317,250 |
Total assets | 89,299,000 | 50,425,000 | 141,677,394 | 142,808,326 | 84,104,799 |
Total liabilities | 9,958,000 | 14,385,000 | 17,993,470 | 9,477,822 | 7,145,630 |
Total equity | 79,341,000 | 36,040,000 | 123,683,924 | 133,330,503 | 76,959,169 |
P&L
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total operating income | 0 | 53,000 | 7,891,998 | 13,300,000 | 13,125,003 |
Total operating costs | 101,841,000 | 109,625,000 | 101,961,280 | 65,452,949 | 47,783,555 |
Operating result | -101,841,000 | -109,572,000 | -94,069,282 | -52,152,949 | -34,658,552 |
Financial income/costs | 945,000 | 4,410,000 | 7,261,889 | 3,081,218 | -658,698 |
Profit before tax | -100,896,000 | -105,162,000 | -86,807,393 | -49,071,731 | -35,317,250 |
Total tax & extraordinary income/cost | 0 | 0 | 0 | 0 | 0 |
Annual Total Result | -100,896,000 | -105,162,000 | -86,807,393 | -49,071,731 | -35,317,250 |
Balance overview
| Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
Total fixed assets | 17,641,000 | 17,303,000 | 6,830,420 | 6,597,350 | 4,524,021 |
Total current assets | 71,658,000 | 33,122,000 | 134,846,974 | 136,210,976 | 79,580,778 |
Total assets | 89,299,000 | 50,425,000 | 141,677,394 | 142,808,326 | 84,104,799 |
Short term debt | 9,958,000 | 14,385,000 | 17,993,470 | 9,477,822 | 7,145,630 |
Long term debt | 0 | 0 | 0 | 0 | 0 |
Total liabilities | 9,958,000 | 14,385,000 | 17,993,470 | 9,477,822 | 7,145,630 |
Contributed capital | 102,676,000 | 7,895,000 | 123,683,924 | 133,330,503 | 76,959,169 |
Retained earnings | -23,335,000 | 28,145,000 | 0 | 0 | 0 |
Total equity | 79,341,000 | 36,040,000 | 123,683,924 | 133,330,503 | 76,959,169 |
Total equity and liabilities | 89,299,000 | 50,425,000 | 141,677,394 | 142,808,326 | 84,104,799 |
Classification
21st company classification
BETA
Scaleup
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification